CClinicalTrials.gg
RecruitingNCT05490238DISCO COMPLEXUpdated Dec 19, 2025

DIStal Versus COnventional Radial Access for COMPLEX Large-bore Percutaneous Coronary Intervention

An interventional study of Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan) in Vascular Access Site Occlusion, sponsored by IGLESIAS Juan Fernando. Recruiting at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Sponsored by IGLESIAS Juan Fernando · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
708
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The use of the distal radial artery has recently emerged as a promising alternative access route to further reduce the risk of radial artery occlusion (RAO) and has been endorsed by recent International Consensus documents. The feasibility of a distal radial access (DRA) for coronary angiography and/or PCI has been demonstrated in several observational clinical registries and small-sized randomized clinical trials. In the recent prospective, multicenter, open label, randomized, controlled DIStal vs Conventional RADIAL access (DISCO RADIAL) trial, DRA was associated with low and similar rates of RAO at discharge when compared to conventional TRA among patients undergoing coronary angiography and/or PCI. There is however limited evidence on the feasibility and safety of 7F DRA for PCI.

In a prospective, multicenter, observational study including 41 patients undergoing CTO PCI using a left DRA with a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan), technical success was achieved in 90.3% of patients and procedural success was achieved in 78.1% of patients. No post-procedural DRA RAO were detected by clinical assessment and Doppler ultrasound examination, and no radial artery occlusions at the site of the forearm were found. Doppler ultrasound imaging of the DRA at one month was available in 67.6% of patients, with only one case (4.3%) of DRA RAO. This proof-of-concept study demonstrates that DRA using a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) for CTO PCI is feasible and associated with a high procedural success rate and low vascular access-site complication rates.

No randomized clinical trial to date has however compared the feasibility and safety of a 7F DRA versus 7F TRA for PCI of complex coronary lesions, such as chronic total occlusions (CTO), left main coronary artery disease, heavily calcified lesions, complex bifurcations, or other complex coronary lesions for whom the operator anticipates that a 7F guiding catheter is indicated.

Read the detailed description

The radial artery has become the standard vascular access site for most percutaneous coronary interventions (PCI) and is recommended by the most recent 2018 European Society of Cardiology/European Association for Cardio-Thoracic Surgery guidelines on myocardial revascularization, irrespective of clinical presentation. Patients undergoing PCI of complex coronary lesions, such as a chronic total occlusion (CTO), left main (LM) coronary artery disease, complex bifurcation lesions, or heavily calcified lesions, have however been either absent or under-represented in most trials supporting these guidelines.

The small size of the radial artery remains an important limitation for the use of large bore guiding catheters (>6 F), restricting thereby the treatment of highly complex lesions through the transradial approach. The 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) is a dedicated radial sheath with a thinner wall and hydrophilic coating. It combines an inner diameter compatible with any 7F guiding catheter and an outer diameter smaller than current 7F sheaths.

A prospective, multicenter, observational study including 60 patients demonstrates that a transradial access (TRA) using the 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) for complex coronary interventions is feasible and associated with a high rate of procedural success and a low rate of vascular complications.

In the Complex Large-Bore Radial Percutaneous Coronary Intervention (COLOR) randomized trial, 388 patients with planned PCI for complex coronary lesions were randomly allocated to a 7F TRA or 7F transfemoral access (TFA). Conventional TRA was associated with a significant reduction in clinically relevant access- site bleeding or vascular complications without affecting procedural success when compared to TFA among patients undergoing complex PCI with a 7F large bore access.

The use of the distal radial artery has recently emerged as a promising alternative access route to further reduce the risk of radial artery occlusion (RAO) and has been endorsed by recent International Consensus documents. The feasibility of a distal radial access (DRA) for coronary angiography and/or PCI has been demonstrated in several observational clinical registries and small-sized randomized clinical trials. In the recent prospective, multicenter, open label, randomized, controlled DIStal vs Conventional RADIAL access (DISCO RADIAL) trial, DRA was associated with low and similar rates of RAO at discharge when compared to conventional TRA among patients undergoing coronary angiography and/or PCI. There is however limited evidence on the feasibility and safety of 7F DRA for PCI. The potential advantages of DRA when compared to TRA are contrasted by a slightly smaller size of the distal radial artery potentially impacting on device selection and procedural planning and by its less predictable course, due to the pronounced tortuosity and angulation of the vessel, leading to an overall higher number of puncture attempts, a longer time to achieve arterial access and a higher rate of access failure. These limitations may preclude the use of DRA for PCI of complex coronary lesions when a large bore guiding catheter is needed. There is however limited evidence on the feasibility and safety of 7F DRA for PCI.

In a prospective, multicenter, observational study including 41 patients undergoing CTO PCI using a left DRA with a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan), technical success was achieved in 90.3% of patients and procedural success was achieved in 78.1% of patients. No post-procedural DRA RAO were detected by clinical assessment and Doppler ultrasound examination, and no radial artery occlusions at the site of the forearm were found. Doppler ultrasound imaging of the DRA at one month was available in 67.6% of patients, with only one case (4.3%) of DRA RAO. This proof-of-concept study demonstrates that DRA using a 7F GLIDESHEATH SLENDER® (Terumo Corp., Tokyo, Japan) for CTO PCI is feasible and associated with a high procedural success rate and low vascular access-site complication rates.

No randomized clinical trial to date has however compared the feasibility and safety of a 7F DRA versus 7F TRA for PCI of complex coronary lesions, such as chronic total occlusions (CTO), left main coronary artery disease, heavily calcified lesions, complex bifurcations, or other complex coronary lesions for whom the operator anticipates that a 7F guiding catheter is indicated.

02

Conditions studied

  • Vascular Access Site Occlusion

Keywords

  • Radial artery access
  • Distal radial artery
  • Complex PCI
03

In context

Lead sponsor

IGLESIAS Juan Fernando is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥18 years.
  • Patients presenting with CCS or ACS, including unstable angina or NSTEMI.
  • Patients planned for PCI of complex coronary lesions, such as CTO, left main coronary artery disease, heavily calcified lesions, complex bifurcations, or other complex coronary lesions in whom the operator anticipates that a 7F guiding catheter is indicated.
  • Patients able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with acute ST-segment elevation myocardial infarction.
  • Patients with cardiogenic shock.
  • Patients on chronic hemodialysis.
  • Patients with contraindications to TRA, such as occlusive upper arm peripheral artery disease, or known anatomic variants prohibiting TRA on both sides.
  • Patients with medical conditions that may cause non-compliance with the study protocol and/or may confound the data interpretation.
  • Patients unable to provide written informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
708 participants (estimated)

Study arms

  • Experimental
    Distal radial access

    Distal radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)

    Procedure: Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)

  • Active comparator
    Conventional radial access

    Conventional radial access using 7Fr Glidesheath Slender sheath (Terumo Corp., Japan)

    Procedure: Complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)

Interventions

  • ProcedureComplex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)

    Large-bore radial access for complex PCI with Ultimaster family drug-eluting stent (Terumo Corp., Japan)

06

What researchers measure

Primary outcomes

  1. Incidence of forearm radial artery occlusion

    US Doppler

    Time frame: At hospital discharge (assessed up to day 5)

Secondary outcomes

  1. Incidence of vascular access site-related bleeding

    EASY criteria and BARC criteria

    Time frame: At hospital discharge (assessed up to day 5)

  2. Incidence of vascular access site-related complication

    Clinical assessment

    Time frame: At hospital discharge (assessed up to day 5)

  3. Incidence of radial artery spasm

    Angiographic assessment

    Time frame: During intervention (up to day 1)

  4. Incidence of distal radial artery occlusion

    US Doppler

    Time frame: At hospital discharge (assessed up to day 5)

  5. Total hemostasis time

    Clinical assessment

    Time frame: At hospital discharge (assessed up to day 5)

  6. Incidence of vascular access site-related pain

    Visual Analogue Scale (VAS, 0-10, lower scores represent less pain)

    Time frame: At hospital discharge (assessed up to day 5)

  7. Incidence of hand dysfunction

    Michigan Hand Outcomes Questionnaire (MHQ: 0-100, lower pain scores denote less pain, other high scores denote better hand performance) and QuickDASH Outcome Measure Questionnaire (0-100, lower scores indicate lower level of disability)

    Time frame: At hospital discharge (assessed up to day 5) and at 1 year

  8. Rate of target lesion failure

    Composite of cardiac death, target vessel myocardial infarction, or clinically indicated target lesion revascularization.

    Time frame: At 1 year

07

Study locations

9 of 9 sites recruiting
  • Clinique St. Joseph Arlon - Groupe Vivalia
    Arlon, Belgium
    • Giuseppe Colletti, MD · Principal investigator
    Recruiting
  • CHU Saint-Pierre
    Brussels, Belgium
    • Panagiotis Xaplanteris, MD · Principal investigator
    Recruiting
  • CHU de Charleroi
    Charleroi, Belgium
    • Adel Aminian, MD · Principal investigator
    Recruiting
  • Hôpital de La Louvière - Site Jolimont
    La Louvière, Belgium
    • Claudiu Ungureanu, MD · Principal investigator
    Recruiting
  • Agaplesion Bethesda Krankenhaus Bergedorf
    Hamburg, Germany
    Recruiting
  • Patras University Hospital
    Pátrai, Greece
    • Grigorios Tsigkas, MD · Principal investigator
    Recruiting
  • Humanitas Research Hospital
    Milan, Italy
    • Gabriele L Gasparini, MD · Principal investigator
    Recruiting
  • Basel University Hospital
    Basel, Basel, Switzerland
    • Gregor Leibundgut, MD · Principal investigator
    Recruiting
  • Geneva University Hospitals
    Geneva, Canton of Geneva 1205, Switzerland
    • Maëlle Achard, RN · Contact · maelle.achard@hcuge.ch · +41795533553
    • Sophie Degrauwe, MD · Principal investigator
    Recruiting
08

References and documents

Publications

  • Iglesias JF, Leibundgut G, Heg D, Gasparini GL, Tsigkas G, Ungureanu C, Colletti G, Degrauwe S, Xaplanteris P, Schenke K, Achim A, van Leeuwen MA, Muresan M, Saito S, Sgueglia GA, Aminian A. Distal versus conventional radial large-bore access for percutaneous coronary intervention of complex coronary lesions: Rationale and design of the DISCO COMPLEX randomized superiority trial. Am Heart J. 2026 Feb;292:107291. doi: 10.1016/j.ahj.2025.107291. Epub 2025 Oct 18. PubMed 41115584 ↗

Individual participant data

Plan to share: Yes — Individual participant data will be shared upon reasonable request to the principal investigator after publication of the study primary and secondary endpoints.

Supporting information: Study protocol, Sap, Icf, Csr

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05490238
Lead sponsor
IGLESIAS Juan Fernando
Collaborators
University of Bern
Responsible party
IGLESIAS Juan Fernando (Principal investigator, University Hospital, Geneva) — Sponsor-investigator
First posted
Aug 5, 2022
Start date
Aug 31, 2023
Primary completion
Jun 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Dec 19, 2025

Study contacts

Véronique Menoni
Contact
veronique.menoni@hug.ch
+41795530516
Juan F. Iglesias, MD
principal investigator · University Hospital, Geneva

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion